Xarelto (active ingredient: rivaroxaban) is a prescription medication used to prevent and treat blood clots. It belongs to a class of medications called factor Xa inhibitors, a type of anticoagulant (blood thinner). Xarelto works by blocking factor Xa, an important protein involved in blood clot formation, helping to reduce the risk of harmful clots.
Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation (NVAF)
Xarelto is used to reduce the risk of stroke and blood clots that can travel to other parts of the body in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.
Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Xarelto is used to treat deep vein thrombosis (DVT), a blood clot that typically forms in the deep veins of the legs, and pulmonary embolism (PE), a blood clot that travels to the lungs. It is also used to help reduce the risk of these conditions occurring again after treatment.
Prevention of Deep Vein Thrombosis (DVT) After Hip or Knee Replacement Surgery
Xarelto helps prevent blood clots from forming after hip or knee replacement surgery. Preventing DVT is important because these clots can break loose and travel to the lungs, causing a pulmonary embolism.
Reduction of Major Cardiovascular Events in CAD and PAD
Xarelto is used to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
Xarelto may be used to reduce the risk of venous thromboembolism (VTE) in certain hospitalized or recently hospitalized patients who are acutely ill and at risk of developing blood clots, provided they do not have a high risk of bleeding.
Prevention and Treatment of VTE in Pediatric Patients
Xarelto is indicated for the prevention of venous thromboembolism (VTE) and the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric patients from birth to less than 18 years of age. Treatment is started after at least 5 days of initial anticoagulant therapy administered by injection or infusion.
REVIEWS